Also the effect of analgesics on the evolution of signs, diagnostic accuracy and outcome were surveyed.
Two hundred sixty-six of 294 respondents in the "experienced" group thought analgesics interfere with the evolution of signs as compared with 189 of 245 respondents in the "less experienced" group.
Table 2 Respondents' views on analgesic interference with evolution of signs, effect on diagnosis and outcome Interference with evolution of signs Yes 455 84.4% No 84 15.6% Effect on diagnosis Enhance 28 5.2% Impair 420 77.9% No effect 91 16.9% Effect on outcome Adverse effect 294 54.5% Beneficial 112 20.8% None 133 24.7%.
Of 245 respondents in the surgical group, 189 thought analgesics interfere with the evolution of signs, while 266 of 294 respondents in the non-surgical group thought the same.
Four hundred fifty-five respondents (84.4%) thought analgesics interfere with the evolution of signs, 420 (77.9%) felt they cause impairment of diagnosis, and 294 (54.5%) thought they have adverse effects on outcome (Table 2).
This is not surprising since the majority of the respondents (84.5%) held the traditional view that analgesics interfere with the evolution of signs, therefore impairing diagnosis (77.9%), and that analgesics have an adverse effect on outcome (54.5%).
Reasons for withholding analgesics were (1) believing that analgesics interfered with evolution of signs (84.4%), (2) believing that the diagnosis would be impaired (77.9%) and (3) believing that analgesics would have an adverse effect on outcome (54.5%).
Mice were checked at least weekly for neurologic clinical signs and were killed when they exhibited signs of distress or confirmed evolution of clinical signs.
When signs occurred, the mice were monitored daily and were sacrificed with an anaesthetic solution overdose (200 µl of 0.8% ketamin –0.12% xylazin) if they exhibited any signs of distress or confirmed evolution of clinical signs of prion disease.
The transfer of CD4+CD25+ cells harvested and sorted from EAE-malaria mice significantly diminished the evolution of clinical signs of EAE (p<0.01) as compared to animals that were immunized only, or even to the group that received CD4+CD25− cells (Fig. 4F).
